|8.65||+0.7100||+8.94%||Vol 569.18K||1Y Perf -37.08%|
|Oct 3rd, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||25.00||Analyst Rating||Strong Buy 1.00|
|Potential %||189.02||Finscreener Ranking||★★★★+ 54.73|
|Insiders Trans % 3/6/12 mo.||-/-100/-100||Value Ranking||★★★+ 53.40|
|Insiders Value % 3/6/12 mo.||-/-100/-100||Growth Ranking||★★★+ 54.26|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||10.55||Earnings Rating||Sell|
|Market Cap||527.83M||Earnings Date||2nd Nov 2023|
Today's Price Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||2nd Nov 2023|
|Estimated EPS Next Report||-0.85|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||517.07K|
|Avg. Monthly Volume||587.88K|
|Avg. Quarterly Volume||413.60K|
Dyne Therapeutics Inc. (NYSE: DYN) stock closed at 7.94 per share at the end of the most recent trading day (a -11.38% change compared to the prior day closing price) with a volume of 469.80K shares and market capitalization of 527.82M. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 36 people. Dyne Therapeutics Inc. CEO is Joshua T. Brumm.
The one-year performance of Dyne Therapeutics Inc. stock is -37.08%, while year-to-date (YTD) performance is -31.49%. DYN stock has a five-year performance of -38.02%. Its 52-week range is between 7.83 and 15.6, which gives DYN stock a 52-week price range ratio of 10.55%
Dyne Therapeutics Inc. currently has a PE ratio of -3.30, a price-to-book (PB) ratio of 2.43, a price-to-sale (PS) ratio of -, a price to cashflow ratio of 3.50, a PEG ratio of -, a ROA of -47.24%, a ROC of -50.15% and a ROE of -54.55%. The company’s profit margin is -14.58%, its EBITDA margin is 18.60%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Dyne Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.85 for the next earnings report. Dyne Therapeutics Inc.’s next earnings report date is 02nd Nov 2023.
The consensus rating of Wall Street analysts for Dyne Therapeutics Inc. is Strong Buy (1), with a target price of $25, which is +189.02% compared to the current price. The earnings rating for Dyne Therapeutics Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Dyne Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Dyne Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 12.77, ATR14 : 0.69, CCI20 : -102.90, Chaikin Money Flow : 0.06, MACD : -0.68, Money Flow Index : 28.09, ROC : -14.99, RSI : 30.28, STOCH (14,3) : 4.93, STOCH RSI : 0.00, UO : 40.96, Williams %R : -95.07), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Dyne Therapeutics Inc. in the last 12-months were: Beskrovnaya Oxana (Sold 2 891 shares of value $37 209 ), Brumm Joshua T (Option Exercise at a value of $286 371), Brumm Joshua T (Sold 325 330 shares of value $4 195 796 ), Farwell Wildon (Sold 1 698 shares of value $21 106 ), HIGH SUSANNA GATTI (Sold 1 625 shares of value $20 199 ), Jason P. Rhodes (Buy at a value of $10 000 017), Jonathan Mcneill (Option Excercise at a value of $14 600), Jonathan McNeill (Sold 87 449 shares of value $1 070 283 ), Joshua Brumm (Sold 0 shares of value $-286 371 ), Joshua Brumm (Sold 332 648 shares of value $4 293 344 ), Joshua T. Brumm (Option Excercise at a value of $216 300), Joshua T. Brumm (Sold 220 640 shares of value $2 763 181 ), McNeill Jonathan (Sold 2 259 shares of value $28 649 ), Oxana Beskrovnaya (Sold 2 096 shares of value $26 267 ), Richard William Scalzo (Sold 0 shares of value $-41 200 ), Richard William Scalzo (Sold 54 324 shares of value $691 520 ), Susanna High (Sold 2 310 shares of value $28 945 ), Wildon Farwell (Sold 9 767 shares of value $127 121 )
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.